๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for partial epilepsy

โœ Scribed by Kang, Huicong ;Liu, Xiaoyan ;Qi, Hu ;Xu, Feng ;Li, Xiang ;Wang, Yuan ;Liu, Zhiguang ;Zhu, Suiqiang

Book ID
107472292
Publisher
Higher Education Press and Springer
Year
2009
Tongue
English
Weight
111 KB
Volume
3
Category
Article
ISSN
1673-7342

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Efficacy and safety evaluation of lorecl
Efficacy and safety evaluation of loreclezole as add-on treatment in therapy-resistant epilepsy patients
โœ T Rentmeester; J Hulsman ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 381 KB

Thirteen drug-resistant epilepsy patients received loreclezole as add-on therapy. The trial lasted 6 months. Loreclezole was dosed to reach a target plasma concentration between 1 and 3 mg/l. The seizure frequency in the total group decreased by 23%. A reduction of 50% or more was observed in four p

A double-blind, placebo-controlled evalu
A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures
โœ T Rentmeester; A Janssen; J Hulsman; F Scholtes; B van der Kleij; J Overweg; J M ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 655 KB

Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on-trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1-2 mg/l. In spite of an antiepileptic therapy, u